In 2017, the FDA approved 12 novel cancer drugs. The agency also approved two chimeric antigen receptor T-cell therapies for blood cancers.

graphic

For 2017, the FDA reported it approved 12 novel cancer drugs, a category that includes drugs with active ingredients not previously approved in the United States, and excludes new applications or combinations of existing drugs. The FDA also greenlighted the first two chimeric antigen receptor T-cell therapies for cancer—tisagenlecleucel (Kymriah; Novartis), for the treatment of B-cell precursor acute lymphoblastic leukemia, and axicabtagene ciloleucel (Yescarta; Kite) for the treatment of certain forms of large B-cell lymphoma.

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

©2018 American Association for Cancer Research.
2018
American Association for Cancer Research.